Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Phenytoin and Formation of T Lymphocyte Rosettes

Phenytoin and Formation of T Lymphocyte Rosettes Abstract • Phenytoin sodium has been associated with the formation of altered T lymphocyte rosettes in vitro. To investigate the clinical relevance of this observation, the formation of T lymphocyte rosettes in nine patients was studied before treatment with phenytoin and after therapeutic concentrations of the drug in plasma were attained. The percentage of total rosette-forming cells found before treatment was not significantly different from the percentage found 24 hours after treatment. Likewise, the percentage of active rosette-forming cells before phenytoin therapy was not significantly less than after therapy. These results suggest that in vivo treatment with phenytoin does not acutely inhibit the formation of T lymphocyte rosettes. References 1. Sorrell TC, Forbes IJ: Depression of immune competence by phenytoin and carbamazepine . Clin Exp Immunol 20:273-285, 1975. 2. Sorrell TC, Forbes IJ, Burness FR, et al: Depression of immunological function in patients treated with phenytoin sodium (sodium diphenylhydantoin) . Lancet 2:1233-1235, 1971.Crossref 3. Grob PJ, Herold GE: Immunological abnormalities and hydantoins . Br Med J 2:561-563, 1972.Crossref 4. Aarli JA: Changes in serum immunoglobulin levels during phenytoin treatment of epilepsy . Acta Neurol Scand 54:423-430, 1976.Crossref 5. MacKinney AA, Booker HE: Diphenylhydantoin effects on human lymphocytes in vitro and in vivo . Arch Intern Med 129:988-992, 1972.Crossref 6. Newcom SR, Kadin ME: T cell leukemia with thymic involution . Cancer 43:622-626, 1979.Crossref 7. Hornby C, Mullen PW: The effects of phenytoin on T lymphocyte enumeration . Br J Pharmacol 61:454, 1977. 8. Neilan BA: Effect of phenytoin on T lymphocyte rosette formation . Curr Ther Res 25:557-563, 1979. 9. Cranford RE, Leppik IE, Patrick B, et al: Intravenous phenytoin: Clinical and pharmacokinetic aspects . Neurology 28:874-880, 1978.Crossref 10. Record KE, Rapp RP, Young AB, et al: Oral phenytoin loading in adults: Rapid achievement of therapeutic plasma levels . Ann Neurol 5:268-270, 1979.Crossref 11. Felsburg PJ, Edelman R, Gilman RH: The active E rosette test: Correlation with delayed cutaneous hypersensitivity . J Immunol 116:1110-1114, 1976. 12. Wybran J, Fudenberg HH: Thymus-derived rosette-forming cells in various human disease states: Cancer, lymphoma, bacterial and viral infection, and other diseases . J Clin Invest 52:1026-1032, 1973.Crossref 13. Kaplan ME, Clark C: Improved rosetting assay for detection of human T lymphocytes . J Immunol Methods 5:131-135, 1974.Crossref 14. Galant SP, Remo RA: β-Adrenergic inhibition of human T lymphocyte rosettes . J Immunol 114:512-513, 1975. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Neurology American Medical Association

Phenytoin and Formation of T Lymphocyte Rosettes

Archives of Neurology , Volume 37 (9) – Sep 1, 1980

Loading next page...
 
/lp/american-medical-association/phenytoin-and-formation-of-t-lymphocyte-rosettes-8EzO0GjDgp
Publisher
American Medical Association
Copyright
Copyright © 1980 American Medical Association. All Rights Reserved.
ISSN
0003-9942
eISSN
1538-3687
DOI
10.1001/archneur.1980.00500580076014
Publisher site
See Article on Publisher Site

Abstract

Abstract • Phenytoin sodium has been associated with the formation of altered T lymphocyte rosettes in vitro. To investigate the clinical relevance of this observation, the formation of T lymphocyte rosettes in nine patients was studied before treatment with phenytoin and after therapeutic concentrations of the drug in plasma were attained. The percentage of total rosette-forming cells found before treatment was not significantly different from the percentage found 24 hours after treatment. Likewise, the percentage of active rosette-forming cells before phenytoin therapy was not significantly less than after therapy. These results suggest that in vivo treatment with phenytoin does not acutely inhibit the formation of T lymphocyte rosettes. References 1. Sorrell TC, Forbes IJ: Depression of immune competence by phenytoin and carbamazepine . Clin Exp Immunol 20:273-285, 1975. 2. Sorrell TC, Forbes IJ, Burness FR, et al: Depression of immunological function in patients treated with phenytoin sodium (sodium diphenylhydantoin) . Lancet 2:1233-1235, 1971.Crossref 3. Grob PJ, Herold GE: Immunological abnormalities and hydantoins . Br Med J 2:561-563, 1972.Crossref 4. Aarli JA: Changes in serum immunoglobulin levels during phenytoin treatment of epilepsy . Acta Neurol Scand 54:423-430, 1976.Crossref 5. MacKinney AA, Booker HE: Diphenylhydantoin effects on human lymphocytes in vitro and in vivo . Arch Intern Med 129:988-992, 1972.Crossref 6. Newcom SR, Kadin ME: T cell leukemia with thymic involution . Cancer 43:622-626, 1979.Crossref 7. Hornby C, Mullen PW: The effects of phenytoin on T lymphocyte enumeration . Br J Pharmacol 61:454, 1977. 8. Neilan BA: Effect of phenytoin on T lymphocyte rosette formation . Curr Ther Res 25:557-563, 1979. 9. Cranford RE, Leppik IE, Patrick B, et al: Intravenous phenytoin: Clinical and pharmacokinetic aspects . Neurology 28:874-880, 1978.Crossref 10. Record KE, Rapp RP, Young AB, et al: Oral phenytoin loading in adults: Rapid achievement of therapeutic plasma levels . Ann Neurol 5:268-270, 1979.Crossref 11. Felsburg PJ, Edelman R, Gilman RH: The active E rosette test: Correlation with delayed cutaneous hypersensitivity . J Immunol 116:1110-1114, 1976. 12. Wybran J, Fudenberg HH: Thymus-derived rosette-forming cells in various human disease states: Cancer, lymphoma, bacterial and viral infection, and other diseases . J Clin Invest 52:1026-1032, 1973.Crossref 13. Kaplan ME, Clark C: Improved rosetting assay for detection of human T lymphocytes . J Immunol Methods 5:131-135, 1974.Crossref 14. Galant SP, Remo RA: β-Adrenergic inhibition of human T lymphocyte rosettes . J Immunol 114:512-513, 1975.

Journal

Archives of NeurologyAmerican Medical Association

Published: Sep 1, 1980

References